Novaspira Biotherapeutics Reports Phase 1 Data for a Novel GPC3x4-1BB Bispecific in Late-Breaking Oral at SITC 2026
Chatham, NJ, November 7, 2026: Novaspira Biotherapeutics today announced the presentation of first-in-human clinical data for BOS-342 (NS-342), a novel GPC3 × 4-1BB bispecific immunotherapy, in patients with advanced hepatocellular carcinoma (HCC).